Compare Quest Diagnostics Inc (DGX) vs WD 40 Company (WDFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs WD 40 Company — how do they compare? Quest Diagnostics Inc trades at $237.51 (market cap $26.21B), while WD 40 Company trades at $231.66 (market cap $3.13B). The key difference: Quest Diagnostics Inc is far larger — about 8.4× WD 40 Company's market cap, and WD 40 Company pays the higher dividend (1.75%). Which is the better fit depends on your goals.
| DGX | WDFC | |
|---|---|---|
Market Cap | $26.21B | $3.13B |
Sector | Health | Technology |
52-Week High | $238.50 | $264.91 |
52-Week Low | $173.49 | $187.52 |
Enterprise Value | $31.97B | $3.18B |
Dividend Yield | 1.45% | 1.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.99, up 0.15% on the day, near its 52-week high. The stock shows strong momentum with consecutive earnings beats in 2026, including Q2 EPS of $3.12 versus $2.82 expected. Revenue growth accelerated to $11.04 billion in 2025, with net income margin at 9.19%. Technical indicators signal a bullish trend, while analyst consensus is a $249.50 price target. Recent news highlights AI integration and raised 2026 outlook amid robust testing demand.
The outlook for DGX is positive, driven by earnings momentum, strategic partnerships, and healthcare demand. Investment opportunity lies in sustained growth and dividend yield, but risks include margin pressure from lower-margin deals and high debt levels. Valuation at a P/E of 25.21 requires continued execution to justify upside.
WDFC trades at $232.50, down 0.86% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings of $2.33 per share, beating estimates, but faces gross margin pressure from input costs. Revenue is projected to grow to $675 million in 2026, though net income may dip slightly. A dividend of $1.02 per share is payable July 31, 2026.
Outlook is mixed: solid brand strength and cash flow support stability, but high valuation ratios and margin pressures pose risks. Analyst consensus is cautious with 71% hold ratings. Key catalysts include execution against growth strategy, while headwinds include cost inflation and competitive challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About WD 40 Company
WD-40 Company is a global marketing organization dedicated to creating 'positive lasting memories' by developing and selling products that solve maintenance and cleaning problems. Built around the legendary WD-40 Multi-Use Product, the company operates an asset-light business model, focusing on brand management and innovation while utilizing a network of contract manufacturers to deliver solutions across the Americas, EIMEA, and Asia-Pacific.
Read more on WDFC →
